Filing Flows › CervoMed (CRVO) › Q4 2024
CervoMed (CRVO) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 17, 2025
CervoMed (CRVO) reported revenue of $2.2M for the fourth quarter 2024 (Q4 2024), -13% from a year earlier and +11% from the quarter before. Operating margin was -334.9%, net loss $6.7M (310.2% of revenue).
CervoMed, Q4 2024: revenue $2.2M (-13% year over year), operating margin -334.9%, net loss $6.7M, operating cash flow −$8.1M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.2M | +11% | -13% |
| Operating profit | −$7.2M | — | — |
| Net earnings | −$6.7M | — | — |
| Operating cash flow | −$8.1M | — | — |
What changed
Revenue was $2.2M in Q4 2024, down 13% year over year and up 11% from the previous quarter.
Operating costs exceeded revenue by $7.2M, an operating margin of -334.9%. Total costs grew 89% against a revenue fall of 13%. The fastest-growing cost line was Research & development (+148%). The quarter ended with a net loss of $6.7M, wider than the previous quarter's $4.8M loss.
Operating cash flow was −$8.1M. Non-cash charges added back $338K of share-based compensation. Working capital and other items used $1.7M.
Questions
What was CervoMed's revenue in the fourth quarter 2024?
CervoMed (CRVO) reported revenue of $2.2M for the fourth quarter 2024 (Q4 2024), -13% from a year earlier and +11% from the quarter before.
Was CervoMed profitable in the fourth quarter 2024?
Operating loss was $7.2M (-334.9% of revenue) and net loss $6.7M.
Source: CervoMed 10-K on SEC EDGAR.